Epicrispr Biotechnologies
Epicrispr Biotechnologies is a biotechnology company developing curative therapies, specifically focusing on gene-modulating therapies for neuromuscular diseases. Their lead program, EPI-321, is a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), targeting the underlying genetic cause of the disease and aiming to silence aberrant gene expression.
Funding Round: Series B
Funding Amount: $68M
Date: 26-Mar-2025
Investors: Ally Bridge Group, SOLVE FSHD, Other investors
Markets: Biotech, Therapeutics, Gene Therapy
HQ: South San Francisco, California, United States
Founded: 2018
Website: https://epicrispr.com/
LinkedIn: https://www.linkedin.com/company/epicrispr-biotechnologies
Twitter: https://twitter.com/EpicrisprBio
Facebook: https://www.facebook.com/Epicbiotech
Crunchbase: https://www.crunchbase.com/organization/epic-bio
Leave a Comment
Comments
No comments yet.